HK Stock Market Move | Joinn Laboratories (06127) rose over 4%, with new orders signed in the first half of the year nearly doubling, as the company continues to advance capacity construction at its two major bases.

Joinn Laboratories (06127) rose over 4%, up 4.15% as of press time, at HK$27.62, with a turnover of HK$181 million. On the news front, Joinn Laboratories previously disclosed its interim results. In the first half of 2026, the company's overall backlog of orders amounted to approximately RMB 3.7 billion, up 60.9% year-on-year; newly signed orders amounted to approximately RMB 2.02 billion, up 98.0% year-on-year, of which new orders signed in 2026Q2 were RMB 1.11 billion, up 88.14% year-on-year and up 21.98% quarter-on-quarter. Western pointed out that the company continues to advance capacity construction. In 2026H1, its Beijing laboratory facility completed a 5,000-square-meter expansion, which will further enhance the company's overall business capacity and operational throughput; in 2026H1, the Guangzhou base project successfully passed the joint acceptance inspection by government authorities, and the company organized multiple departments to complete internal acceptance confirmation for all disciplines of the project. China Securities Co., Ltd. stated that in the first half of the year, the company's newly signed orders achieved both volume and price growth, with price changes contributing more, and the gross margin of projects corresponding to newly signed orders in the period has recovered to the 30%- 35% range. The bank believes that the growth in innovative drug project signings, combined with an increase in long-cycle specialty projects, is expected to optimize the order structure and enhance revenue visibility; as newly signed orders in 26H1 gradually revenue and profit in 2027-2028, the company's revenue growth rate and gross margin level in the next two years are expected to improve significantly, and the ample backlog at period-end will also provide support for subsequent revenue growth and profit recovery in laboratory services.